Zoetis Inc. (NYSE:ZTS) Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 94.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,628 shares of the company's stock after selling 292,568 shares during the quarter. Jefferies Financial Group Inc.'s holdings in Zoetis were worth $2,709,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its position in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the period. Navigoe LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp bought a new position in Zoetis during the 4th quarter worth approximately $44,000. Finally, Asset Planning Inc bought a new position in Zoetis during the 4th quarter worth approximately $58,000. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS traded up $2.68 during mid-day trading on Friday, hitting $163.03. 2,391,686 shares of the stock were exchanged, compared to its average volume of 2,513,944. The company has a market cap of $72.58 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a 50-day moving average of $156.49 and a two-hundred day moving average of $165.56. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.38 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZTS. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Piper Sandler raised their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and a consensus target price of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.